SCHEMBL20984476

SCHEMBL20984476

COc1cccc(Cl)c1NNC(=O)C(=O)NNc1c(Cl)cccc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 5/20 0.43
▸ MAPT P10636 3/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ P2RX7 Q99572 1/20 0.41
▸ FABP4 P15090 1/20 0.41
▸ CLCN2 P51788 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ S1PR2 O95136 1/20 0.40
▸ S1PR4 O95977 1/20 0.40
▸ S1PR3 Q99500 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20984589 0.88 CA12 (0.48) GAAMAPTALDH1A1CA12CA1
SCHEMBL20984504 0.82 GAA (0.58) GAAMAPTALDH1A1PKMP2RX7
SCHEMBL20984492 0.80 SMN1; SMN2 (0.50) GAAALDH1A1PKMCA12CA1
SCHEMBL9188769 0.78 MAPK1 (0.47) GAAMAPTCA12CA1CA2
SCHEMBL20984523 0.78 MAPT (0.39) GAAMAPTALDH1A1FABP4SMN1; SMN2
SCHEMBL20984757 0.77 GAA (0.52) GAAMAPTALDH1A1CA12CA1
Oxalic Acid SCHEMBL28377990 0.75 CA12 (0.44) GAAMAPTALDH1A1CA12CA1
SCHEMBL20984873 0.75 ALDH1A1 (0.54) GAAMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL28384149 0.74 CA12 (0.42) MAPTALDH1A1CA12CA1CA2
SCHEMBL4510997 0.74 PDK1 (0.51) GAAMAPTSMN1; SMN2S1PR2S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040938-B2 Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) 2021-06-22 — — US claimed
CN-107663161-B Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt 上海惠和化德生物科技有限公司 2020-04-10 — — CN claimed
US-20190152896-A1 Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) 2019-05-23 — — US claimed
US-11040938-B2 Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) 2021-06-22 — — US disclosed
CN-107663161-B Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt 上海惠和化德生物科技有限公司 2020-04-10 — — CN disclosed
US-20190152896-A1 Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) 2019-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040938-B2 Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts HPD, TYR, PDK2 GAA 237/4885MAPT 2735/4885ALDH1A1 379/4885
US-20190152896-A1 Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts HPD, TYR, PDK2 GAA 237/4885MAPT 2735/4885ALDH1A1 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback